GLPwatch
Saxenda vs Soliqua
Drug comparison
Last updated 2026-05-28 15:46 UTCSaxenda (liraglutide by Novo Nordisk) is a once-daily injection approved for treating obesity, while Soliqua (lixisenatide by Sanofi) is a once-daily injection approved for managing type 2 diabetes. Both are given under the skin, but Saxenda uses liraglutide and Soliqua uses lixisenatide as their active ingredients.
AI summary of the sources below.
| Saxenda | Soliqua | |
|---|---|---|
| Active ingredient | liraglutide | lixisenatide |
| Manufacturer | novo-nordisk | sanofi |
| Route | subcutaneous injection | subcutaneous injection |
| FDA-approved for | obesity | type 2 diabetes |
| Label updated | 2026-02-25 | 2026-03-18 |